FDA Approved: KADCYLA — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for KADCYLA (ado-trastuzumab emtansine) submitted by Genentech, Inc. The submission status is listed as AP.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Kadcyla (ado-trastuzumab emtansine)

Snippet

SUPPL AP for KADCYLA (ADO-TRASTUZUMAB EMTANSINE)